Century Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 19, 2025
IPSC$1.68-7.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · Year Ended · · Year Ended · | |||||||
| · · December 31, 2024 · · December 31, 2023 · | |||||||
| · · · | |||||||
| Cash flows from operating activities · · | |||||||
| Net loss | | $(126,566) | | $(136,673) | | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | ||
| Depreciation | | 13,304 | | 13,044 | | ||
| Amortization of deferred financing cost | | | — | | | 94 | |
| Non-cash operating lease (benefit) | | | (271) | | | (1,196) | |
| Stock based compensation | | 12,688 | | 14,622 | | ||
| Impairment | | | 4,327 | | | 16,365 | |
| Amortization of investments | | | (4,812) | | | (3,984) | |
| Change in fair value of contingent liabilities | | | (1,356) | | | — | |
| Decrease in lease liability due to lease termination | | | 959 | | | — | |
| Change in deferred tax liability | | | 870 | | | — | |
| Change in operating assets and liabilities: | | | | | | ||
| Escrow deposit | | — | | 220 | | ||
| Prepaid expenses and other assets | | 543 | | 667 | | ||
| Operating lease liability | | | (3,365) | | | 13,819 | |
| Deferred revenue | | | (6,589) | | | (2,235) | |
| Accounts payable | | (1,469) | | (2,361) | | ||
| Accrued expenses and other liabilities | | 1,602 | | (730) | | ||
| Net cash used in operating activities | | (110,135) | | (88,348) | | ||
| | | | | | | | |
| Cash flows from investing activities | | | | ||||
| Acquisition of property and equipment | | (154) | | (13,736) | | ||
| Acquisition of fixed maturity securities, available for sale | | (119,548) | | (209,034) | | ||
| Sale of fixed maturity securities, available for sale | | 176,792 | | 283,902 | | ||
| Acquisition of Clade Therapeutics, Inc., net of cash acquired | | (9,608) | | — | | ||
| Net cash provided by investing activities | | 47,482 | | 61,132 | | ||
| | | | | | | | |
| Cash flows from financing activities | | | | ||||
| | | | | | | | |
| Proceeds from issuance of common stock and ESPP | | | 141 | | | 516 | |
| Payments on long term debt | | | — | | | (10,241) | |
| Proceeds from ATM, net of issuance costs | | | 17,829 | | | — | |
| Proceeds from PIPE, net of issuance costs | | 56,593 | | — | | ||
| Net cash provided by (used in) financing activities | | 74,563 | | (9,725) | | ||
| | | | | | | | |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | | 11,910 | | (36,941) | | ||
| | | | | | | | |
| Cash, cash equivalents and restricted cash, beginning of period | | 49,303 | | 86,244 | | ||
| | | | | | | | |
| Cash, cash equivalents and restricted cash, end of period | | $61,213 | | $49,303 | | ||
| | | | | | | | |
| Supplemental disclosure of cash and non-cash operating activities: | | | | | | | |
| Cash paid for interest | | $— | | $586 | | ||
| Cash paid for income tax | | $501 | | $2,521 | | ||
| | | | | | | | |
| Supplemental disclosure of non-cash investing and financing activities: | | | | | |||
| Stock issued in connection with the Acquisition | | $15,154 | | $— | | ||
| Purchase of property and equipment, accrued and unpaid | | $— | | | 352 | | |
| Landlord paid leasehold improvements | | $934 | | $— | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.